Literature DB >> 8746632

Expression, purification, and characterization of acylphosphatase muscular isoenzyme as fusion protein with glutathione S-transferase.

A Modesti1, N Taddei, M Bucciantini, M Stefani, B Colombini, G Raugei, G Ramponi.   

Abstract

A genetic construct consisting of the synthetic gene coding for human muscle acylphosphatase linked to the gene for glutathione S-transferase has been prepared. This gene was transformed into and expressed by the Escherichia coli strains DB1035 and TB1, respectively. The fusion protein was purified by affinity chromatography and subsequently cleaved to the fully active acylphosphatase, which was further purified by gel filtration chromatography. Such a purification procedure is very rapid and suitable for obtaining considerable amounts of enzyme at a very high yield. The purified human muscle acylphosphatase was fully active and showed structural features, as well as kinetic and stability parameters, identical to those of the native enzyme.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8746632     DOI: 10.1006/prep.1995.0011

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  10 in total

1.  Designing conditions for in vitro formation of amyloid protofilaments and fibrils.

Authors:  F Chiti; P Webster; N Taddei; A Clark; M Stefani; G Ramponi; C M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase.

Authors:  Francesco Bemporad; Niccolò Taddei; Massimo Stefani; Fabrizio Chiti
Journal:  Protein Sci       Date:  2006-04       Impact factor: 6.725

3.  Preliminary characterization of two different crystal forms of acylphosphatase from the hyperthermophile archaeon Sulfolobus solfataricus.

Authors:  Simone Zuccotti; Camillo Rosano; Francesco Bemporad; Massimo Stefani; Martino Bolognesi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2004-12-24

4.  Initial denaturing conditions influence the slow folding phase of acylphosphatase associated with proline isomerization.

Authors:  T A Pertinhez; D Hamada; L J Smith; F Chiti; N Taddei; M Stefani; C M Dobson
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

5.  Structural and dynamics characteristics of acylphosphatase from Sulfolobus solfataricus in the monomeric state and in the initial native-like aggregates.

Authors:  Katiuscia Pagano; Francesco Bemporad; Federico Fogolari; Gennaro Esposito; Paolo Viglino; Fabrizio Chiti; Alessandra Corazza
Journal:  J Biol Chem       Date:  2010-03-11       Impact factor: 5.157

6.  Rapid oligomer formation of human muscle acylphosphatase induced by heparan sulfate.

Authors:  Neda Motamedi-Shad; Tommaso Garfagnini; Amanda Penco; Annalisa Relini; Federico Fogolari; Alessandra Corazza; Gennaro Esposito; Francesco Bemporad; Fabrizio Chiti
Journal:  Nat Struct Mol Biol       Date:  2012-04-22       Impact factor: 15.369

7.  Acylphosphatase possesses nucleoside triphosphatase and nucleoside diphosphatase activities.

Authors:  P Paoli; G Camici; G Manao; E Giannoni; G Ramponi
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

8.  Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway.

Authors:  Neda Motamedi-Shad; Elodie Monsellier; Silvia Torrassa; Annalisa Relini; Fabrizio Chiti
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

9.  Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain.

Authors:  F Chiti; M Bucciantini; C Capanni; N Taddei; C M Dobson; M Stefani
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

10.  Interaction between acylphosphatase and SERCA in SH-SY5Y cells.

Authors:  C Cecchi; G Liguri; A Pieri; D Degl'Innocenti; C Nediani; C Fiorillo; P Nassi; G Ramponi
Journal:  Mol Cell Biochem       Date:  2000-08       Impact factor: 3.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.